In February 2026, a pharmaceutical company that has been selling diabetes and heart medicines in India for six decades agreed to pay ₹1,583 crore ($164.9 million, converted at $1 ≈ ₹96.0) for 79% of a nutraceutical startup that had never once turned a profit. Wellbeing Nutrition’s most recently reported year showed a loss of about ₹30-38 crore on revenue of ₹119-170 crore, depending on whose numbers you use — yet USV, the maker of Glycomet GP and Ecosprin, still signed the largest cheque in its history to take control of it.
That contradiction sits at the centre of this deep dive: how does a lossmaking, seven-year-old supplements brand from Mumbai end up valued at more than thirteen times its own revenue by a company that has spent sixty years selling prescription medicine, not gummies. The answer runs through a founder who was told by every large pharma company he approached that India did not need a wellness category, three funding rounds that went from angel cheques to a strategic conglomerate, and a business model that still has not fully solved the arithmetic of paid growth.
Quick facts
| Company | Wellbeing Nutrition (legal entity: Nutritionalab Private Limited) |
| Founded | 2019, Mumbai |
| Founder(s) | Avnish Chhabria (Founder); Saurabh Kapoor (Co-founder and Chief Business Officer) |
| Businesses | Direct-to-consumer nutraceuticals — vitamins, gummies and melts, marine collagen, protein, greens, kids’ nutrition — sold via its own site, marketplaces, quick commerce and 6,000-plus retail outlets in India, the US, the UK and the UAE |
| Latest FY revenue | ₹119 crore in FY25 as per MCA filings (Inc42 Datalabs); the company itself has stated ₹170 crore for the same year (Entrackr, August 2025) |
| Latest FY profit/loss | Loss of ₹38 crore in FY25 per MCA-filing-based data (Inc42); the company has stated a narrower loss of about ₹30 crore (Entrackr, August 2025) |
| Listed | Private; USV signed a definitive agreement in February 2026 to acquire a 79% stake |
| Market value / last valuation | ₹1,583 crore ($164.9 million), per the all-cash USV deal announced in February 2026 |
| Key shareholders / CEO | Avnish Chhabria (Founder, retaining a minority stake); USV (79% post-deal); Fireside Ventures and Hindustan Unilever divesting a combined stake as part of the transaction |
What they do
Wellbeing Nutrition sells science-formatted nutraceuticals to urban Indian consumers who find tablets and capsules unappealing but are willing to pay a premium for supplements that feel more like a lifestyle product than medicine. Its catalogue runs to more than 30 stock-keeping units across roughly 19 functional categories — melt-in-mouth strips, slow-release capsules, marine collagen peptides, daily fibre blends, vegan protein and a children’s range co-branded with Disney and Marvel — manufactured in US FDA-registered and USDA Organic-certified facilities and sold through its own website, Amazon and Nykaa, quick commerce apps, and a physical retail footprint of pharmacies, modern trade chains, malls and airports that had grown past 6,000 outlets across India, the US, the UK and the UAE by the time of the USV deal in February 2026, according to Entrepreneur India’s reporting of the transaction.
The origin
Founder Avnish Chhabria came to nutraceuticals from retail and food, not from pharma or medicine. Before Wellbeing Nutrition he had been Managing Partner at Eliya, an organic coconut water brand, founded and run Stylista, a social fashion commerce platform, and worked as Chief Operating Officer at the conglomerate Viiking Ventures, according to his own profile carried by Entrepreneur India. The insight for Wellbeing Nutrition came from a simple observation about how differently Indian and American consumers treated supplements: in the US, people routinely bought vitamins and supplements off the back of their own bloodwork, with no doctor’s prescription involved, while in India the entire category was mediated by physicians and dominated by generic, low-trust tablets. Chhabria has described being rebuffed on this thesis by the industry itself — in his words to Entrepreneur India, “every nutritionist said it wasn’t possible” and “every large pharmaceutical company told me India didn’t need to be in health and wellness.” He built the company instead on three bets, as Fireside Ventures later summarised its own investment thesis: that Indian consumers did not trust the quality of commodity supplements, that younger urban buyers had a cultural aversion to pills, and that categories such as beauty-from-within, cognition, sleep and sports nutrition were structurally underpenetrated in India. Co-founder Saurabh Kapoor, who had earlier co-founded a digital marketing agency, joined to build the brand’s direct-to-consumer and content engine.
The struggle years
The company started small and stayed unprofitable for years even as its revenue climbed. It launched with just two products, GrandMa’s Kadha and Daily Greens, and Fireside Ventures’ own account of the investment says early monthly net revenue was only about ₹80 lakh — a fraction of what a venture-backed consumer brand typically needs to justify institutional capital. Revenue did grow: from ₹42 crore in FY23 to ₹72 crore in FY24, according to figures cited by Entrepreneur India and Entrackr. But so did the losses. Entrackr’s reporting on a debt raise in April 2025 put the FY24 net loss at ₹32 crore against that ₹72 crore of operating revenue — meaning the company was still losing more than 40 paise for every rupee it brought in, four years after its first institutional round. By early 2025, instead of raising a fresh priced equity round, Wellbeing Nutrition turned to debt: in April 2025 it raised ₹25 crore through optionally convertible debentures led by pharmaceutical packaging company ACG-Capsules (₹10 crore), with Maheshwari Investors, MGB Advisors and Atmos Finance putting in ₹5 crore each, explicitly to fund working capital rather than growth capital, per Entrackr’s reporting at the time. A debt raise rather than an equity round, at a point when the company’s losses had not meaningfully narrowed, is itself a signal of how tight the path to profitability still looked less than a year before the company would be bought out.
The turning point
The turning point was not a product launch or a viral marketing moment — it was USV’s decision, in February 2026, to buy control of a company that was still losing money. On one side of the table sat USV, a pharmaceutical group that reported FY25 revenue of about ₹5,200 crore and employs more than 7,000 people, according to Medical Dialogues’ reporting of the deal — a business roughly 44 times the size of the one it was acquiring. On the other side sat Wellbeing Nutrition, coming off a year in which its own MCA-filing-based numbers showed a ₹38 crore loss on ₹119 crore of revenue (Inc42 Datalabs), even after 65.3% year-on-year growth. USV agreed to pay ₹1,583 crore in an all-cash, definitive agreement for 79% of Nutritionalab Private Limited, Wellbeing Nutrition’s parent entity — about 35% of that stake coming from founder Avnish Chhabria and 44% from existing shareholders, per Entrepreneur India’s reporting, with Chhabria committing to stay on until March 2028. For early backer Hindustan Unilever, the numbers on its side of the trade were explicit: Entrackr reported that HUL sold its entire 19.8% stake for approximately ₹307 crore, more than four times the roughly ₹70 crore it had put in through the 2022 Series B round. Fireside Ventures, the earliest institutional investor, also exited as part of the combined 40% stake sold by the two investors.
The money behind it
- Series A, June 2021: $2.2 million led by Fireside Ventures — the first institutional round, validating the science-led, direct-to-consumer nutraceutical thesis (YourStory and Entrepreneur India, June 2021).
- Series B, December 2022: $10 million led by Hindustan Unilever and Fireside Ventures, with both taking board seats — earmarked to push into offline retail (a target of 5,000-plus touchpoints) and scale digital marketing reach to 100 million people within a year (BusinessToday, December 2022).
- Debt round, April 2025: ₹25 crore raised via optionally convertible debentures led by ACG-Capsules, alongside Maheshwari Investors, MGB Advisors and Atmos Finance — used for working capital rather than expansion (Entrackr, April 2025).
- Total disclosed funding before the 2026 exit: about $14 million (roughly ₹120 crore) across equity and debt, per Entrackr’s reporting in April 2025 and February 2026.
- Exit, February 2026: USV signs a definitive agreement for 79% of parent Nutritionalab Private Limited at a ₹1,583 crore valuation; Fireside Ventures and HUL together divest a combined 40% stake, with HUL’s 19.8% alone reported sold for about ₹307 crore (Entrackr, February 2026).
How it makes money
- Revenue comes from selling supplements at a premium to commodity tablets, across the company’s own website, marketplaces (Amazon, Nykaa), quick commerce apps, and offline retail spanning pharmacies, modern trade, malls and airports (Entrackr, August 2025).
- The product range spans 30-plus SKUs across roughly 19 functional categories, including melts, slow-release capsules, marine collagen peptides, daily fibre and vegan protein, sold under celebrity-linked marketing partnerships with Rakulpreet Singh, Mira Kapoor and Dulquer Salmaan, and a Disney/Marvel-branded kids’ range (Fireside Ventures; Inc42, December 2022).
- Average order value on the direct-to-consumer channel runs at about ₹1,900, with a company-reported repeat-purchase rate of around 45%, according to Fireside Ventures’ account of the investment.
- Reported gross margin sits at around 60%, per the same Fireside Ventures account — a healthy figure for a consumer brand, but one that has not translated into profit at the net level.
- The part people get wrong: high gross margin does not equal a profitable business here. On MCA-filing-based numbers, Wellbeing Nutrition still lost ₹38 crore against ₹119 crore of revenue in FY25 (Inc42 Datalabs) — the gap between gross margin and net result is largely performance marketing, celebrity endorsements and the cost of building out a 6,000-plus-outlet offline network, none of which come cheap for a brand still establishing category trust.
The numbers
| Year (₹ crore) | Revenue | Profit / (loss) |
| FY23 | 42 | Not disclosed in the filings reviewed |
| FY24 | 72 | (32) |
| FY25 (MCA filing, per Inc42 Datalabs) | 119 | (38) |
| FY25 (company-stated, per Entrackr) | 170 | (30) |
The FY25 gap is worth naming rather than smoothing over: Inc42’s Datalabs figures, sourced from MCA filings, put FY25 revenue at ₹119 crore with a ₹38 crore loss, while Entrackr, citing the company directly, reported FY25 revenue of about ₹170 crore and a loss of around ₹30 crore. Both figures are reported here because they conflict and neither has been independently reconciled in the public record available this session; readers should treat the ₹170 crore figure as company-stated and the ₹119 crore figure as filing-based. On either measure, revenue roughly doubled or grew by more than 65% year-on-year, and the company remained loss-making.
Where the money comes from
- Online channels — the company’s own site, Amazon, Nykaa and quick commerce — made up about 70% of sales in the period reported, despite the brand’s growing offline push (Entrackr, August 2025).
- Offline retail — pharmacies, modern trade, malls and airports — accounted for about 25% of sales, spread across more than 3,700 stores as of August 2025, a footprint that grew to more than 6,000 outlets by the time of the USV deal in February 2026 (Entrackr, August 2025; Entrepreneur India, February 2026).
- Exports made up the remaining 5-10% of sales, with the company selling into more than 25 countries including the US, the UK and the UAE (Entrackr, August 2025; Entrackr, February 2026).
- The surprise: a company whose entire founding story is “digital-first D2C” already earns a quarter of its revenue offline, and its next chapter under USV leans further into pharmacy-style distribution and regulatory credibility rather than more performance marketing.
The risks
- Persistent losses despite scale: even after 65.3% year-on-year revenue growth, Wellbeing Nutrition posted a ₹38 crore loss on ₹119 crore of revenue in FY25 on filing-based numbers (Inc42 Datalabs) — the unit economics of paid customer acquisition in nutraceuticals have not yet resolved into a profitable standalone business.
- Regulatory and category-boundary risk: nutraceuticals sit at the edge of food and drug regulation in India, and the company’s own disclosed plan to expand into a GLP-1-linked therapy brand called “usema” is explicitly contingent on an existing exclusivity period lapsing, per Entrepreneur India’s reporting of the USV deal — a reminder that adjacent-category expansion here runs into licensing constraints, not just market demand.
- Channel concentration: about 70% of sales run through the company’s own site, marketplaces and quick commerce apps (Entrackr, August 2025), leaving revenue exposed to platform commission rates, algorithm changes and discounting cycles that Wellbeing Nutrition does not control.
- Post-acquisition retention risk: founder Avnish Chhabria has committed to stay on only until March 2028 under the terms of the USV deal (Entrepreneur India, February 2026), after which the brand’s continuity depends on a management team operating under a much larger parent’s board oversight rather than founder-led decision-making.
The takeaway
Growth that impresses investors and profitability that satisfies accountants are not the same test, and founders chasing the first often assume the second will follow automatically. Wellbeing Nutrition never fully closed that gap on its own — it was still losing tens of crores a year, seven years in, when USV signed its cheque. What it did prove, repeatedly, is that a well-formulated, well-distributed brand in an underpenetrated category can keep growing revenue at 65% or more a year even while unprofitable, and that this kind of growth is itself a saleable asset to a strategic buyer who has the balance sheet and distribution to fix the economics that the startup could not fix by itself. The lesson for anyone building a category-defining consumer brand is not to wait for net profit before seeking the next milestone; it is to be honest, the way the public numbers here force us to be, about which parts of the story are proven and which are still promises.
Frequently asked questions
What does Wellbeing Nutrition sell?
It sells nutraceutical supplements — vitamins, gummies and melts, marine collagen, protein, greens and a kids’ range — positioned as a more palatable, science-formulated alternative to traditional tablets, sold through its own website, marketplaces, quick commerce and a growing offline retail network.
Who founded Wellbeing Nutrition and when?
Avnish Chhabria founded the company in 2019 in Mumbai, later joined by co-founder Saurabh Kapoor as Chief Business Officer.
How much funding did Wellbeing Nutrition raise before being acquired?
About $14 million (roughly ₹120 crore) in disclosed funding, including a $2.2 million Series A in 2021 led by Fireside Ventures, a $10 million Series B in 2022 led by Hindustan Unilever and Fireside Ventures, and a ₹25 crore debt round in 2025 led by ACG-Capsules.
What is Wellbeing Nutrition’s valuation?
USV’s February 2026 agreement to acquire a 79% stake valued the company at ₹1,583 crore ($164.9 million at $1 ≈ ₹96.0), as reported by Entrackr, Business Standard and Entrepreneur India.
Is Wellbeing Nutrition profitable?
No. On MCA-filing-based figures reported by Inc42 Datalabs, it posted a ₹38 crore loss on ₹119 crore of revenue in FY25; the company itself has cited a narrower loss of about ₹30 crore on ₹170 crore of revenue for the same year.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Entrackr, “USV acquires 79% stake in Wellbeing Nutrition at Rs 1,583 Cr valuation”, February 2026.
- Business Standard, “USV to acquire 79% stake in Wellbeing Nutrition at ₹1,583 cr valuation”, February 2026.
- Entrepreneur India, “USV Acquires 79 Percent Stake in Wellbeing Nutrition for INR 1,583 Cr”, February 2026.
- Medical Dialogues, “USV Acquires 79% Stake in Wellbeing Nutrition, Values D2C Startup at Rs 1,583 Cr”, February 2026.
- Entrackr, “Wellbeing Nutrition claims Rs 170 Cr revenue in FY25; retail share at 25%”, August 2025.
- Inc42 Datalabs, “Wellbeing Nutrition Financials — Revenue, P&L & Cash Flow”, accessed September 2026.
- Entrackr, “D2C brand Wellbeing Nutrition raises debt”, April 2025.
- BusinessToday, “Wellbeing Nutrition raises $10 million in a Series B round led by HUL, Fireside Ventures”, December 2022.
- Inc42, “Bollywood Personality Mira Kapoor Backs D2C Startup Wellbeing Nutrition”, December 2022.
- YourStory / Entrepreneur India, coverage of Wellbeing Nutrition’s $2.2 million Series A led by Fireside Ventures, June 2021.
- Fireside Ventures, “Wellbeing Nutrition: From Thesis to Exit”, 2026.
- Entrepreneur India, profile of founder Avnish Chhabria and Wellbeing Nutrition’s path into D2C wellness.
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.